Health Companies
Waiv ๐ 
Custom Surgical ๐ฉ๐ช 
Brightheart ๐ซ๐ท 
Flinn ๐ฆ๐น 
Tandem ๐บ๐ธ 
Vicentra ๐ณ๐ฑ 
Qura ๐ฎ๐น 
TandemAI ๐บ๐ธ 
Hippocratic AI ๐บ๐ธ 
Tozaro ๐ฌ๐ง Latest Deals in Health
Invenirex, a Newcastle-based biotech, raised ยฃ2 million in seed funding led by DSW Ventures, with participation from XTX Ventures and Cambridge Technology Capital. The companyโs DNA nanotechnology platform detects diseases earlier than current methods, achieving 200-fold greater sensitivity. Pilot tests have shown promising results in diagnostics and vaccine manufacturing.
INVENIREXInvestors: DSW Ventures, XTX Ventures, Cambridge Technology Capital
Invenirex, a Newcastle-based biotech, has raised ยฃ2 million in seed funding led by DSW Ventures, with participation from XTX Ventures, Cambridge Technology Capital, and angel investors. The companyโs DNA nanotechnology platform detects diseases at early stages, achieving 200-fold greater sensitivity than current methods, with promising pilot results in diagnostics.
Investors: DSW Ventures, XTX Ventures, Cambridge Technology Capital
No Barrier, a San Francisco-based company specializing in AI-powered medical translation, raised $2.7 million in seed funding led by A-Squared Ventures, Esplanade Ventures, Rock Health Capital, and Fusion. The funds will be used to expand operations and development efforts.
NO BARRIERInvestors: A-Squared Ventures, Esplanade Ventures, Rock Health Capital, Fusion
No Barrier, a San Francisco-based company specializing in AI-powered medical translation, raised $2.7 million in seed funding led by A-Squared Ventures, Esplanade Ventures, Rock Health Capital, and Fusion. The funds will be used to expand operations and development efforts.
Investors: A-Squared Ventures, Esplanade Ventures, Rock Health Capital, Fusion
No Barrier, a healthcare AI company addressing language barriers in clinical settings, has raised $2.7 million in an oversubscribed seed round led by A-Squared Ventures, Esplanade Ventures, Rock Health Capital, and Fusion. The funding will enhance its real-time medical interpretation technology deployment.
NO BARRIERInvestors: A-Squared Ventures, Esplanade Ventures, Rock Health Capital, Fusion
Voize, a Berlin-based AI solutions provider for nursing care, raised $50 million in Series A funding led by Balderton Capital, with participation from HV Capital, Redalpine, and Y Combinator. The funds will be used to expand in Europe and enter the US market.
VOIZEInvestors: Balderton Capital, HV Capital, Redalpine, Y Combinator
Voize, a nursing care company, raised $50 million in a Series A funding round led by Balderton Capital, with participation from HV Capital, Redalpine, and Y Combinator. Voize addresses the nursing shortage and administrative burdens by providing an AI companion that streamlines documentation, currently used by over 75,000 nurses in 1,100 care facilities.
Investors: Balderton Capital, HV Capital, Redalpine, Y Combinator
Nursing care company Voize raised $50 million in Series A funding led by Balderton Capital, with participation from HV Capital, Redalpine, and Y Combinator. Voize addresses the global nursing shortage by providing AI tools that reduce administrative burdens, allowing over 75,000 nurses in 1,100 facilities to save up to 30% of their time.
Investors: Balderton Capital, HV Capital, Redalpine, Y Combinator
Berlin-based Voize has secured $50 million in Series A funding, led by Balderton Capital, with participation from HV Capital, Redalpine, and Y Combinator. The companyโs AI platform reduces nurses' documentation time, allowing them to focus on patient care. Currently, over 1,100 care facilities use Voize, benefiting more than 75,000 nurses.
Investors: Balderton Capital, HV Capital, Redalpine, Y Combinator
Beacon Biosignals has raised $86 million in an oversubscribed Series B funding round, led by Innoviva and Google Ventures, among others. The company develops AI-powered biomarkers for neurological and psychiatric diseases, aiming to enhance clinical adoption and precision medicine. Total funding now exceeds $121 million.
BEACON BIOSIGNALSInvestors: Innoviva, Google Ventures
T-THERAPEUTICS
Barcelona-based Holo has raised โฌ1 million in pre-seed funding, led by Calm/Storm Ventures and Mission VC, to enhance health monitoring through an app that integrates lab testing and wearables. The platform analyzes over 110 biomarkers, aiming to empower users in preventive health management.
HOLOInvestors: Calm/Storm Ventures, Mission VC
Clairity, a Boston-based precision health company, has raised $43 million in Series B funding, led by Ace Global Equity and Santรฉ Ventures, to enhance its AI-driven risk prediction tools for medical imaging. The investment aims to accelerate commercialization and expand into new disease areas.
CLAIRITYInvestors: Ace Global Equity, Santรฉ Ventures
Parallel has raised $100 million in a Series A funding round, achieving a $740 million valuation. Co-led by Kleiner Perkins and Index Ventures, the funding aims to enhance web infrastructure for AI agents. Key investors include Spark Capital and existing backers Khosla Ventures and First Round Capital.
PARALLELInvestors: Kleiner Perkins, Index Ventures, Spark Capital, Khosla Ventures, First Round Capital
Beacon Biosignals, a Boston-based neurotechnology company, raised $86 million in a Series B funding round led by Catalio Capital Management, with participation from Innoviva, Google Ventures, and others. The company aims to enhance brain health diagnostics using AI-driven biomarkers, having raised over $121 million to date.
Investors: Catalio Capital Management, Innoviva, Google Ventures
Beacon Biosignals, a Boston-based neurotechnology company, secured an $86 million Series B funding round led by Catalio Capital Management, with participation from Innoviva, Google Ventures, and others. The company develops AI-driven diagnostics for brain health, aiming to create the largest neurodiagnostic dataset and improve drug development.
Investors: Catalio Capital Management, Innoviva, Google Ventures
Boston-based Beacon Biosignals raised $86 million in a Series B funding round led by Catalio Capital Management, with participation from Innoviva, Google Ventures, and others. The neurotechnology company focuses on AI-driven diagnostics for brain health, aiming to build the largest neurodiagnostic dataset and improve drug development.
Investors: Catalio Capital Management, Innoviva, Google Ventures
T-therapeutics, a UK-based biotech developing next-generation T cell receptor therapeutics for cancer and autoimmune diseases, raised an additional โฌ27.5 million ($32 million) in Series A funding, bringing the total to โฌ78.2 million ($91 million). New investors Tencent and BGF joined existing backers like Sofinnova Partners and Sanofi Ventures.
Investors: Tencent, BGF, Sofinnova Partners, Sanofi Ventures